When Inato Co-Founder and Chief Strategy Officer, Liz Beatty, sat down with Dr. Daniel Fox and Monica Cuitiva from “Save Our Sites” (SOS) (full recording HERE) their conversation made one thing clear: Inato is not just another clinical trials platform.
As a global tech-powered marketplace that operates entirely free for sites, the SOS team emphasized that Inato is changing the game and bringing major efficiencies to both sites and sponsors. Leveraging technology and transparency, Inato redefines feasibility, empowering sites in communities around the world to participate in the RIGHT trials – the ones that align with their capabilities, goals, and patient populations, and the ones they’ll excel most in. “Often times we put in double effort on things that don’t need to have double effort… To me that’s the most powerful part [of Inato], not to mention the possibility to get more studies in a shorter period!” said host and co-founder of Latinos in Clinical Research, Monica Cuitiva, sharing her team’s experience using Inato.
To kick off the conversation, Liz shared a quick overview of how Inato’s marketplace works:
“This is a real business model designed to truly enhance site success and, therefore, sponsor success. It only makes sense. This is a big deal. This is going to change how we do research, faster, better, for better results.” – Dr. Daniel Fox
Alleviating Site Burdens and Challenges
When asked how Inato is “Saving Our Sites” – Liz addressed five significant challenges faced by clinical trial sites, sharing Inato’s tech-powered solutions to lighten the load (all at no cost!):
Challenge #1: Limited access to trials
Challenge #2: Limited information leads to pursuit of the wrong trials
“Educating sponsors on the importance of sharing maximum details up-front is something we’ve spent a lot of time on so we can post these trials with as much transparency as possible. Then we use our technology to put the requirements into the algorithms for matching the right sites for that particular opportunity.” – Liz Beatty
Challenge #3: Time spent applying to trials
“We’re trying to completely stop feasibility questionnaires. Sites should not need to complete these long questionnaires... Let’s take all the work out of filling out the same questions over and over again. This is an area where we can use technology to do this – to reuse information and even use AI to pre-fill data based on particular trial requirements. For example, 40% of sites selected on Inato have been selected more than once for a trial. So the next time they work with us, maybe 50% or 70% of the information has already been collected.” – Liz
Challenge #4: Limited ability to stand out to sponsors, build trust, and get selected
“We spend a lot of time with our sponsors saying there may be many reasons to pick different types of sites, so you can work with Inato to find the right mix of sites to meet your goals, not just the top-tiered sites overall.
Maybe you don’t have a competing trial in a competitive disease area, and that could separate you from others also interested in that opportunity. We also ask about diversity and representation and the different patient populations you support, which is really specific to the outreach and relationships at your center – it’s not just about census data.” – Liz Beatty
Challenge #5: Sponsor response delays and no feedback
Reasons Not to Join Inato: 3 Myths Debunked
“I have to know, I’m sitting here thinking FREE, totally here for site success, no strings attached, no-brainer, so why would sites not join Inato?” – Dr. Daniel Fox
Wrapping up the conversation, Liz shared these 3 common misconceptions that tend to keep sites from signing up, along with her thoughts on each:
“Having all of the connections at all the pharmaceutical companies is very hard to manage. If the trials are available on Inato, it makes it much easier instead of having to hunt down the different trial teams at the pharmaceutical companies.” – Liz Beatty
With that, the team closed the session with an emphatic note to sites from Dr. Fox:
“This isn’t a scheme. This isn’t a gimmic. This is a real business model designed to truly enhance site success and, therefore, sponsor success. It only makes sense. I highly, highly recommend reaching out to Inato, going to their website (inato.com) and signing up. See what you can do to join the 3,600+ sites already working with them across the 70+ countries. This is a big deal. This is going to change how we do research, faster, better, for better results.” – Dr. Daniel Fox
On The Horizon
“Inato started as a kind of site-sponsor matchmaker of trials -- so where do you want to take this?” – Dr. Daniel Fox
Dr. Fox asked Liz where Inato is headed, to which she shared plans for driving efficiencies beyond site selection through activation. She talked about reducing a start-up process that can take up to 9 months down to 3-4 weeks with new innovations in the platform for both sites and sponsors.